

N.B. The English text is an in-house translation

The board of directors' of Swedish Orphan Biovitrum AB (publ) statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act

In view of the board of directors' proposal on an authorization for the board of directors to decide on a directed offer to acquire all of the company's issued series C shares, the board of directors hereby makes the following statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act.

The board of directors is convinced that the implementation of the Share Programs 2008-2011 (the "Share Programs") will be beneficial to both the company and its shareholders. The repurchase of the series C shares constitutes a step in the implementation of the Share Programs and the purpose is to create share delivery capacity for the company pursuant to these programs. The intention is that the repurchased series C shares shall be converted to common shares in the number that is required to fulfill the commitments. The converted common shares will thereafter be transferred free of charge to the employees that are intended to participate in the Share Programs and to secure for future cash flow effects due to payments of social security costs connected with the Share Programs, and have as their purpose to fulfill the company's obligations towards the employees that can be entitled to shares upon fulfillment of the performance conditions pursuant to the programs.

The board of directors is of the opinion, in view of the above, that the proposed value distributions are warranted with respect to the amount of the equity required by the nature, scope and risks associated with the business, as well as the company's and the group's consolidation requirements, liquidity and overall financial position. The board of directors has also considered other known circumstances that have not been taken up within the framework of the information above, and in doing so has found nothing to suggest that the proposed value transfers are not warranted.

Stockholm, March 2011

Swedish Orphan Biovitrum AB (publ)
The board of directors